Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Incyte Corp 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 USA

www.incyte.com P: 302-498-6700

Description:

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

Key Statistics

Overview:

Market Capitalization, $K 11,859,464
Enterprise Value, $K 8,646,084
Shares Outstanding, K 224,526
Annual Sales, $ 3,696 M
Annual Net Income, $ 597,600 K
Last Quarter Sales, $ 1,013 M
Last Quarter Net Income, $ 201,080 K
EBIT, $ 620,530 K
EBITDA, $ 703,190 K
60-Month Beta 0.65
% of Insider Shareholders 17.50%
% of Institutional Shareholders 96.97%
Float, K 185,234
% Float 82.50%
Short Volume Ratio 0.48

Growth:

1-Year Return -29.07%
3-Year Return -38.28%
5-Year Return -29.60%
5-Year Revenue Growth 96.38%
5-Year Earnings Growth 228.05%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.06 on 02/13/24
Latest Earnings Date 04/30/24
Earnings Per Share ttm 2.68
EPS Growth vs. Prev Qtr -9.89%
EPS Growth vs. Prev Year 86.36%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/01/00

INCY Ratios

Ratio
Price/Earnings ttm 19.67
Price/Earnings forward 13.88
Price/Earnings to Growth 1.23
Return-on-Equity % 12.56%
Return-on-Assets % 9.64%
Profit Margin % 16.17%
Debt/Equity 0.00
Price/Sales 3.20
Price/Cash Flow 21.86
Price/Book 2.30
Book Value/Share 23.16
Interest Coverage 328.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar